Q-omics provides the consensus-scored PROKR1 profile across patient tissues and cancer cell-line models. PROKR1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, PROKR1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PROKR1 RNA expression shows 16,108 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, COAD, and THYM as cancer lineages where PROKR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROKR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROKR1 survival associations across molecular data types. PROKR1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROKR1 RNA expression–survival associations across cancer types. High PROKR1 expression shows unfavorable associations in THCA, UCEC, SKCM and ACC, but favorable associations in SCLC and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for PROKR1 RNA expression.
This table summarizes PROKR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PROKR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROKR1 shows lower tumor expression in COAD, BRCA, KICH and READ and higher tumor expression in UCEC and KIRP. The COAD box plot shows higher PROKR1 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with PROKR1 in patient tissues and cancer cell lines. In patient samples, PROKR1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROKR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
